Pharmaceutical company Boehringer Ingelheim will cap patients’ out-of-pocket costs at $35 per month for all of its inhaler products and devices, officials announced on March 7.
The cap will begin on June 1 and will apply to eligible patients, the German drugmaker said in a statement.
